A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
复制标题
DOI：
10.1212/wnl.51.2.583
复制
发表时间：
1998-08-01
期刊：
影响因子：
9.9
通讯作者：
Dobbins, T
中科院分区：
文献类型：
--
作者：
Borasio, GD;Robberecht, W;Dobbins, T
为了测试重组人类胰岛素样生长因子-I（RHIGF-I）的安全性和功效，随机分配了来自八个欧洲中心的183名患者接受双盲安慰剂（n = 59）或Rhigf-i 0.1 mg/ kg/day（n = 124）皮下持续9个月。在研究完成时，主要疗效结果度量（通过Appel ALS评级量表所评估的疾病进展的变化）显示治疗组之间没有显着差异。 rhigf-i似乎是安全且耐受良好的。
To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.